The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading ... s already-approved Leqembi (lecanemab), which works in a similar ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

AN ALZHEIMER'S drug hailed as a 'miracle' medicine for dementia may cause life-threatening brain bleeds in a third of patients who take it, warns a new study. The medication has previously been ...

But some experts have long warned that side effects of the drug — called donanemab — massively ... similar Alzheimer's drug called lecanemab, as both produced benefits 'too small' to ...

Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Studies have ...

Eisai and Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) dominate the landscape, winning approvals in the US in 2023 and 2024 respectively. Leqembi is forecast to see $5.3bn ...

In nearly 20 years, aside from cholinesterase inhibitors, memantine is the only drug approved for the treatment of Alzheimer's disease (AD). Memantine is an uncompetitive N-methyl-D-aspartate ...